Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30019942 | 1.00 | TLR2 (0.52) | TLR2SIRT2KMT2AMEN1ALDH1A1 | |
| SCHEMBL30020633 | 0.98 | TLR2 (0.53) | TLR2SIRT2KMT2AMEN1ALDH1A1 | |
| SCHEMBL30019865 | 0.96 | TLR2 (0.50) | TLR2SIRT2KMT2AMEN1ALDH1A1 | |
| SCHEMBL30020706 | 0.96 | TLR2 (0.50) | TLR2SIRT2KMT2AMEN1ALDH1A1 | |
| SCHEMBL12356377 | 0.94 | TLR2 (0.54) | TLR2SIRT2KMT2AMEN1ALDH1A1 | |
| SCHEMBL27148382 | 0.94 | TLR2 (0.51) | TLR2SIRT2KMT2AMEN1ALDH1A1 | |
| SCHEMBL27248175 | 0.92 | KMT2A (0.49) | TLR2SIRT2KMT2AMEN1ALDH1A1 | |
| SCHEMBL30020181 | 0.91 | TLR2 (0.50) | TLR2SIRT2KMT2AMEN1ALDH1A1 | |
| SCHEMBL24235747 | 0.91 | KMT2A (0.47) | TLR2SIRT2KMT2A | |
| SCHEMBL30020899 | 0.89 | KMT2A (0.53) | TLR2SIRT2KMT2ASIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199663-A1 | Cyclopolyphosphazenes, Related Methods of Preparation and Methods of Use | UNITED STATES DEPARTMENT OF ENERGY | 2024-06-20 | — | — | US | disclosed |
| EP-4326741-A1 | CYCLOPOLYPHOSPHAZENES, RELATED METHODS OF PREPARATION AND METHODS OF USE | University of Saskatchewan (CA) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022221959-A1 | CYCLOPOLYPHOSPHAZENES, RELATED METHODS OF PREPARATION AND METHODS OF USE | UNIVERSITY OF SASKATCHEWAN (CA) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199663-A1 | Cyclopolyphosphazenes, Related Methods of Preparation and Methods of Use | PHOSPHO1, TOP2B, TOP2A | TLR2 1176/4885SIRT2 4503/4885KMT2A 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.